leisure time -WSS

leisure time

author：knowledge 2025-09-27 13:02:49 - browse：356

Diversity in clinical trials concept — Adobe

The persistent lack of diversity among participants in clinical trials is a critical issue that is harming both populations that have long been left out of pivotal medical studies and the entire biomedical research enterprise, according to the authors of a report released Tuesday by the National Academies of Sciences, Engineering and Medicine.

Describing the need to move away from trials that focus largely on white men as “urgent,” the report’s authors called for a paradigm shift that gives less power to institutions that fund and conduct clinical research and more to communities under study. The sternly worded report said funding to include and recruit more diverse participants should be a priority that is enforced and said such investments could eventually lead to massive cost savings as the nation’s health disparities are reduced.

“An equitable clinical research enterprise would include trials and studies that match the demographics of the disease burden under study,” the report said. “However, we remain far from achieving this goal.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Violet CEO on training clinicians to promote more inclusive care

WSS

House looks to weaken Medicare negotiation

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Violet CEO on training clinicians to promote more inclusive care

Kenai launches with $82 million for Parkinson’s stem cell therapy

FDA does about

House looks to weaken Medicare negotiation

entertainment

leisure time

hotspot

Apple is now the first public company to be valued at $3 trillion

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

In Memoriam: Notable people who died in 2023

ALS groups 'won't be played again' by the FDA, drug sponsors

Medicare details structure of new drug price negotiation program

AstraZeneca loses challenge to Medicare drug price negotiation

Supreme Court strikes down use of affirmative action

Keeping primary care docs in field isn't impossible, says AAFP CEO

Psychedelics group wrestles with new pharma identity

FogPharma raises $145 million in rare Series E round

leisure time

AstraZeneca loses challenge to Medicare drug price negotiation

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

How to fix the rural physician shortage in the U.S.

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Obesity now affects over 1 billion people worldwide, study finds

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

explore

explore

entertainment

hotspot